Research published in the Journal of Physical Chemistry B reveals that an innovative blood test could detect Alzheimer’s disease up to 17 years earlier than conventional methods. This test employs an immuno-infrared sensor (iRS) to identify abnormal protein changes in blood samples, which are linked to both Alzheimer’s and Parkinson’s diseases. The study, based on a large population sample of 10,000 participants, achieved an accuracy of 0.82 in predicting Alzheimer’s risk, and 94% accuracy for individuals with early memory issues. Additionally, the sensor demonstrated high sensitivity and specificity for Parkinson's disease when tested on spinal fluid samples. However, the test is not yet approved for mass use and requires further validation, including regulatory certification in Europe and FDA approval in the U.S. Limitations of the study include reliance on existing research rather than new clinical trials, and some results are from preprint studies that have not undergone peer review. The corresponding author, Klaus Gerwert, has ties to the commercialisation of this technology.